Status: Recruiting
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Participants needed: 50
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Mar 5, 2026Locations: 1
Eligibility criteria
Patients with AML or biphenotypic or bilineage leukemia (including a myeloid com... [+11]
Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (F... [+3]